Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma

Trial Profile

Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Isotretinoin (Primary) ; Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary) ; Sargramostim (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 11 Jun 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top